Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 10/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18210065 | 1.00 | RORC (0.40) | RORCNR1H2EPHX2USP2SMN1; SMN2 | |
| SCHEMBL21908773 | 0.86 | EPHX2 (0.39) | RORCNR1H2EPHX2USP2SMN1; SMN2 | |
| SCHEMBL28708135 | 0.84 | RORC (0.41) | RORCNR1H2EPHX2USP2SMN1; SMN2 | |
| SCHEMBL24695414 | 0.84 | NR1H2 (0.41) | RORCNR1H2EPHX2USP2SMN1; SMN2 | |
| SCHEMBL27171881 | 0.84 | NR1H2 (0.41) | RORCNR1H2EPHX2USP2SMN1; SMN2 | |
| SCHEMBL24087434 | 0.84 | NR1H2 (0.41) | RORCNR1H2EPHX2USP2SMN1; SMN2 | |
| SCHEMBL13419535 | 0.80 | USP2 (0.46) | RORCNR1H2EPHX2USP2SMN1; SMN2 | |
| SCHEMBL15812124 | 0.79 | EPHX2 (0.42) | RORCNR1H2EPHX2USP2SMN1; SMN2 | |
| SCHEMBL23807876 | 0.79 | EPHX2 (0.42) | RORCNR1H2EPHX2USP2SMN1; SMN2 | |
| SCHEMBL29049020 | 0.79 | EPHX2 (0.42) | RORCNR1H2EPHX2USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3288943-B1 | PYRROLO[2,3-B]PYRAZINYL ACRYLAMIDES AND EPOXIDES THEREOF AS INHIBITORS OF JANUS KINASE | PFIZER (US) | 2022-09-28 | — | — | EP | disclosed |
| US-10703756-B2 | Pyrrolo[2,3-D]pyrimidinyl, pyrrolo[2,3-B]pyrazinyl, pyrrolo[2,3-B]pyridinyl acrylamides and epoxides thereof | PFIZER INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190002466-A1 | PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL, PYRROLO[2,3-B]PYRIDINYL ACRYLAMIDES AND EPOXIDES THEREOF | PFIZER INC. (US) | 2019-01-03 | — | — | US | disclosed |
| EP-3288943-A1 | PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL, PYRROLO[2,3-B]PYRIDINYL ACRYLAMIDES AND EPOXIDES THEREOF | Pfizer Inc (US) | 2018-03-07 | — | — | EP | disclosed |
| WO-2016178110-A1 | PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL, PYRROLO[2,3-B]PYRIDINYL ACRYLAMIDES AND EPOXIDES THEREOF | PFIZER INC. (US) | 2016-11-10 | — | — | WO | disclosed |
| US-9045436-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-06-02 | — | — | US | disclosed |
| US-8466282-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-18 | — | — | US | disclosed |
| US-20120264733-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | SCOHIA PHARMA, INC. (JP) | 2012-10-18 | — | — | US | disclosed |
| US-20110178057-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-07-21 | — | — | US | disclosed |
| US-20100056497-A1 | AMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2010-03-04 | — | — | US | disclosed |
| EP-2119702-A1 | AMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2009-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264733-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | REN, AGT, ACE | RORC 779/4885NR1H2 548/4885EPHX2 180/4885 |
| US-20110178057-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | REN, AGT, ACE | RORC 619/4885NR1H2 338/4885EPHX2 432/4885 |
| US-20190002466-A1 | PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL, PYRROLO[2,3-B]PYRIDINYL ACRYLAMIDES AND EPOXIDES THEREOF | JAK2, JAK3, JAK1 | RORC 2881/4885NR1H2 4812/4885EPHX2 235/4885 |
| US-10703756-B2 | Pyrrolo[2,3-D]pyrimidinyl, pyrrolo[2,3-B]pyrazinyl, pyrrolo[2,3-B]pyridinyl acrylamides and epoxides thereof | JAK2, JAK3, JAK1 | RORC 2881/4885NR1H2 4812/4885EPHX2 235/4885 |
| US-20100056497-A1 | AMIDE DERIVATIVE | REN, AGTR1, AGTR2 | RORC 3508/4885NR1H2 811/4885EPHX2 2169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.